Compare NDLS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NDLS | SCYX |
|---|---|---|
| Founded | 1995 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 60.4M |
| IPO Year | 2013 | 2014 |
| Metric | NDLS | SCYX |
|---|---|---|
| Price | $13.75 | $4.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 28.8K | ★ 329.4K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $495,089,000.00 | $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $608.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.37 | N/A |
| 52 Week Low | $0.47 | $0.57 |
| 52 Week High | $13.95 | $5.62 |
| Indicator | NDLS | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 63.74 | 72.96 |
| Support Level | $0.59 | $0.67 |
| Resistance Level | $13.95 | $5.62 |
| Average True Range (ATR) | 1.02 | 0.27 |
| MACD | 0.06 | 0.26 |
| Stochastic Oscillator | 90.15 | 73.19 |
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.